Vistagen Therapeutics, Inc. (VTGN) stock
VTGNNasdaqPharmaceutical PreparationsFiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 9/3073% below fair value
$0.18+0.00 (+0.95%)
Close on Nov 13, 2026Market cap $8.01MP/E –Yield –
Vistagen Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Vistagen Therapeutics's total debt was $87.30K at Sep 30, 2020. For fiscal 2020 it was $0. The highest annual figure on record is $1.44M in fiscal 2014.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2020 | Mar 31, 2020 | $0 | – |
| FY2018 | Mar 31, 2018 | $0 | – |
| FY2017 | Mar 31, 2017 | $0 | -100.0% |
| FY2016 | Mar 31, 2016 | $27.20K | -23.6% |
| FY2015 | Mar 31, 2015 | $35.60K | -97.5% |
| FY2014 | Mar 31, 2014 | $1.44M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | $87.30K | – |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | $124.70K | – |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | $0 | – |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | $0 | – |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | $0 | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | $0 | – |
See a number that looks wrong?